HomeTagsATG-101

ATG-101

Biotechnology

Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101

PR Newswire - August 3, 2022

Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology,...

Biotechnology

Antengene Announces IND Approval in China for the Phase I Study of ATG-101 for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

PR Newswire - March 10, 2022

Antengene Corporation Limited, a leading innovative commercial stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and...

Biotechnology

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

PR Newswire - December 20, 2021

Antengene Corporation Limited, a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, announced...